Findings

What do systematic reviews say?

Ignored "—": search terms need at least 3 characters.

6 questions · 6 findings · 1 reviews · Neuromuscular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 16.7%Low 3 · 50%Moderate 2 · 33.3%High 0 · 0%

Rituximab vs placebo

Number of participants improved in disability · patients with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies

Rituximab may leads to higher number of participants improved in disability compared with placebo (low certainty).

1 finding from 1 review

Immunotherapy for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies 2016 · Cochrane Headline outcomes only
RR 3.51 [1.3, 9.45]
2 studies · 73 participants
Low

Rituximab vs placebo

Mean improvement in disability · patients with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies

1 finding from 1 review

Immunotherapy for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 73 participants
Low

Rituximab vs placebo

Improvement in 10‐metre walk time at 8 to 12 months1 · patients with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies

1 finding from 1 review

Immunotherapy for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 68 participants
Moderate

Rituximab vs placebo

Participant subjective impression of change stable or improved at 8 to 12 months · patients with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies

Rituximab may leads to higher participant subjective impression of change stable or improved at 8… compared with placebo (low certainty).

1 finding from 1 review

Immunotherapy for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies 2016 · Cochrane Headline outcomes only
RR 1.86 [1.27, 2.71]
2 studies · 70 participants
Low

Rituximab vs placebo

Change in serum IgM paraprotein concentration 8 months after treatment1 · patients with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies

1 finding from 1 review

Immunotherapy for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 26 participants
Moderate

Rituximab vs placebo

Any adverse event · patients with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies

It is very uncertain whether rituximab changes any adverse event compared with placebo (very low certainty).

1 finding from 1 review

Immunotherapy for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies 2016 · Cochrane Headline outcomes only
RR 1.18 [0.84, 1.66]
2 studies · 80 participants
Very low